Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Mid cap

Caplin Point posts its Q4 FY26 earnings call transcript.

A routine regulatory filing of a completed event. The transcript adds nothing beyond the live call on May 14.


Mkt cap₹19,109 cr
P/E29.80×
ROE18.81%
Debt / eq.0.00
Div yld0.16%
May 14, 2026 Date of the earnings call whose transcript was filed.

What's new

  • Caplin Point posted the full transcript of its Q4 FY26 earnings call on its website.
  • The call was held on May 14, 2026.
  • The filing is a procedural step under SEBI LODR regulations.

Why this matters

This is compliance, not news. The transcript is a public record of a discussion the market already had. It carries no new data, guidance, or strategic pivot that would require an investor to update a model.

What we're watching

  • Whether any follow-up commentary from the call alters prior estimates.
  • The company's next quarterly results for fresh financial data.

The full read

Caplin Point has filed the transcript of its Q4 FY26 earnings call, held on May 14, 2026. This is a procedural post. SEBI rules require it. The document captures the live discussion but offers no revision to numbers, no new commentary on strategy, and no surprise that would change a pre-existing view. It is the paperwork for an event that is already over. The call itself, not this archive, is where the analytical work was done. There is nothing new to act on. The next data point is the next quarterly result.

Questions answered

What does this filing contain?
The complete transcript of Caplin Point's Q4 FY26 earnings call, which took place on May 14, 2026.
Why is the company filing this now?
SEBI's Listing Obligations and Disclosure Requirements mandate that listed firms publish earnings call transcripts on their websites after the event.
Is there any new information for investors?
No. The rationale confirms the transcript introduces no new financials, operational updates, or forward guidance beyond what was stated during the live call.
Mentioned: Caplin Point Laboratories · Q4 FY26 · SEBI LODR
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Caplin Point Laboratories Ltd.

Pharmaceuticals
₹15,389 cr
P/E 24.00×

Latest quarter · Mar 2026

Sales₹600 cr
Net profit₹173 cr
Op. margin+34.0%
EPS₹22.38

Strength & growth

Debt / equity0.00×
Current ratio6.97×
Sales CAGR+21.6%
EPS CAGR+27.6%